New blood thinner vicagrel tested against clopidogrel in healthy volunteers

NCT ID NCT07067775

Completed Knowledge-focused Sponsor: Jiangsu vcare pharmaceutical technology co., LTD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study tested two blood-thinning drugs, vicagrel and clopidogrel, in 18 healthy adults with a specific gene type (CYP2C19 normal metabolizers). The goal was to compare how the body absorbs and processes each drug. Researchers measured drug levels in the blood and their effects on clotting. This is a first step to see if vicagrel might work better than the standard drug clopidogrel.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vicagrel and clopidogrel
What this could lead to: If vicagrel shows better absorption or action than clopidogrel, it could lead to a more effective anti-clotting drug for heart patients.
What could go wrong: This is a very early, small study in 18 healthy people, not patients. Results may not predict real-world benefits or safety in those with heart conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROME

Contacts and locations

Locations

The First Hospital of Jilin University

Changchun, Jilin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.